HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
NEFL
neurofilament light chain
Chromosome 8 Β· 8p21.2
NCBI Gene: 4747Ensembl: ENSG00000277586.5HGNC: HGNC:7739UniProt: P07196
309PubMed Papers
23Diseases
0Drugs
51Pathogenic Variants
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
intermediate filament organizationaxonal transport of mitochondrionneurofilament bundle assemblyneurofilamentCharcot-Marie-Tooth disease type 2ECharcot-Marie-Tooth disease type 1FAutosomal dominant Charcot-Marie-Tooth disease type 2ECharcot-Marie-Tooth disease, dominant intermediate G
✦AI Summary

NEFL encodes neurofilament light chain, a key intermediate filament protein essential for maintaining neuronal structure and function. As a structural constituent of the cytoskeleton, NEFL participates in neurofilament bundle assembly and axonal transport processes, working alongside other neurofilament proteins NEFM and NEFH to maintain neuronal caliber 1. The protein serves as a critical biomarker of neuroaxonal damage, with elevated plasma levels indicating neuronal injury across multiple neurological conditions 23. In multiple sclerosis, increased NEFL concentrations reflect acute inflammatory disease activity and axonal damage during relapses, making it valuable for monitoring treatment response 3. NEFL also functions as an early biomarker for dementia, with plasma levels increasing up to 15 years before clinical diagnosis and correlating with cognitive decline 45. Pathogenic variants in NEFL cause various forms of Charcot-Marie-Tooth disease, including demyelinating, axonal, and intermediate forms, demonstrating the protein's critical role in peripheral nerve function 1. Additionally, NEFL expression influences neuroblastoma susceptibility and progression, with higher expression levels associated with better survival outcomes 6. The protein's levels are elevated in amyotrophic lateral sclerosis and correlate with disease progression markers 7.

Sources cited
1
NEFL encodes neurofilament light chain and pathogenic variants cause various forms of Charcot-Marie-Tooth disease
PMID: 38578900
2
NEFL serves as a biomarker of neuroaxonal degeneration, with serum levels increasing after EBV seroconversion in MS
PMID: 35025605
3
NEFL concentrations reflect axonal damage from inflammatory disease activity in multiple sclerosis and help monitor treatment response
PMID: 41015047
4
Peripheral NEFL levels are elevated up to 15 years before dementia diagnosis and correlate with cognitive decline
PMID: 38735950
5
Plasma NEFL demonstrates strong predictive value for Alzheimer's disease and vascular dementia
PMID: 40873267
6
NEFL expression influences neuroblastoma susceptibility and progression, with higher expression associated with better survival
PMID: 25312269
7
NEFL levels are elevated in ALS plasma and correlate with disease progression markers
PMID: 39913612
Disease Associationsβ“˜23
Charcot-Marie-Tooth disease type 2EOpen Targets
0.79Strong
Charcot-Marie-Tooth disease type 1FOpen Targets
0.79Strong
Autosomal dominant Charcot-Marie-Tooth disease type 2EOpen Targets
0.76Strong
Charcot-Marie-Tooth disease, dominant intermediate GOpen Targets
0.71Strong
Charcot-Marie-Tooth diseaseOpen Targets
0.64Moderate
autosomal dominant intermediate Charcot-Marie-Tooth disease type GOpen Targets
0.50Moderate
peripheral neuropathyOpen Targets
0.49Moderate
genetic disorderOpen Targets
0.49Moderate
Charcot-Marie-Tooth disease type 2Open Targets
0.37Weak
Charcot-Marie-Tooth disease type 2B5Open Targets
0.37Weak
Peripheral demyelinationOpen Targets
0.34Weak
auditory neuropathyOpen Targets
0.34Weak
Decreased nerve conduction velocityOpen Targets
0.34Weak
Distal muscle weaknessOpen Targets
0.34Weak
Hand muscle atrophyOpen Targets
0.34Weak
developmental disorder of mental healthOpen Targets
0.27Weak
Distal lower limb muscle weaknessOpen Targets
0.27Weak
Pes cavusOpen Targets
0.27Weak
Sensorineural hearing impairmentOpen Targets
0.27Weak
sensorineural hearing lossOpen Targets
0.27Weak
Charcot-Marie-Tooth disease, axonal, type 2EUniProt
Charcot-Marie-Tooth disease, demyelinating, type 1FUniProt
Charcot-Marie-Tooth disease, dominant intermediate GUniProt
Pathogenic Variants51
NM_006158.5(NEFL):c.23C>T (p.Pro8Leu)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 8
NM_006158.5(NEFL):c.293A>G (p.Asn98Ser)Pathogenic
Charcot-Marie-Tooth disease type 1F|not provided|Charcot-Marie-Tooth disease type 2E|Charcot-Marie-Tooth disease, dominant intermediate G|Charcot-Marie-Tooth disease|Charcot-Marie-Tooth disease type 1F;Charcot-Marie-Tooth disease type 2E;Charcot-Marie-Tooth disease, dominant intermediate G|Developmental disorder;Sensorineural hearing loss disorder|NEFL-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 98
NM_006158.5(NEFL):c.1186G>A (p.Glu396Lys)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E|Charcot-Marie-Tooth disease, dominant intermediate G|Charcot-Marie-Tooth disease|Charcot-Marie-Tooth disease type 1F
β˜…β˜…β˜†β˜†2025β†’ Residue 396
NM_006158.5(NEFL):c.1150A>T (p.Ile384Phe)Pathogenic
Charcot-Marie-Tooth disease type 2E|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 384
NM_006158.5(NEFL):c.556G>T (p.Glu186Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 186
NM_006158.5(NEFL):c.268G>A (p.Glu90Lys)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E
β˜…β˜…β˜†β˜†2025β†’ Residue 90
NM_006158.5(NEFL):c.1195C>T (p.Arg399Ter)Pathogenic
not provided|Charcot-Marie-Tooth disease type 1F|Charcot-Marie-Tooth disease type 2E
β˜…β˜…β˜†β˜†2024β†’ Residue 399
NM_006158.5(NEFL):c.1261C>T (p.Arg421Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E|Charcot-Marie-Tooth disease|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 421
NM_006158.5(NEFL):c.292A>C (p.Asn98His)Likely pathogenic
not provided|Charcot-Marie-Tooth disease, dominant intermediate G
β˜…β˜…β˜†β˜†2024β†’ Residue 98
NM_006158.5(NEFL):c.23C>G (p.Pro8Arg)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E|Charcot-Marie-Tooth disease|Inborn genetic diseases
β˜…β˜…β˜†β˜†2024β†’ Residue 8
NM_006158.5(NEFL):c.54C>G (p.Tyr18Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β˜…β˜…β˜†β˜†2023β†’ Residue 18
NM_006158.5(NEFL):c.64C>T (p.Pro22Ser)Pathogenic
Charcot-Marie-Tooth disease type 2E|not provided|Charcot-Marie-Tooth disease type 1C|Peripheral neuropathy;Pes cavus;Distal lower limb muscle weakness|Peripheral neuropathy;Decreased nerve conduction velocity;Peripheral demyelination;Hand muscle atrophy;Distal muscle weakness|Charcot-Marie-Tooth disease type 1F|Inborn genetic diseases
β˜…β˜…β˜†β˜†2022β†’ Residue 22
NM_006158.5(NEFL):c.417C>G (p.Tyr139Ter)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E
β˜…β˜…β˜†β˜†2022β†’ Residue 139
NM_006158.5(NEFL):c.18C>G (p.Tyr6Ter)Pathogenic
Charcot-Marie-Tooth disease type 1F
β˜…β˜…β˜†β˜†2022β†’ Residue 6
NM_006158.5(NEFL):c.865G>T (p.Glu289Ter)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E
β˜…β˜…β˜†β˜†2022β†’ Residue 289
NM_006158.5(NEFL):c.171C>G (p.Tyr57Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β˜…β˜†β˜†β˜†2024β†’ Residue 57
NM_006158.5(NEFL):c.417C>A (p.Tyr139Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β˜…β˜†β˜†β˜†2024β†’ Residue 139
NM_006158.5(NEFL):c.223C>T (p.Gln75Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β˜…β˜†β˜†β˜†2024β†’ Residue 75
NM_006158.5(NEFL):c.720C>G (p.Tyr240Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β˜…β˜†β˜†β˜†2024β†’ Residue 240
NM_006158.5(NEFL):c.1099C>T (p.Arg367Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β˜…β˜†β˜†β˜†2024β†’ Residue 367
View on ClinVar β†—
Related Genes
DESProtein interaction100%KIF5AProtein interaction100%KIF5BProtein interaction100%KIF5CProtein interaction100%KLC1Protein interaction100%SYT1Protein interaction100%
Tissue Expression6 tissues
Brain
100%
Ovary
0%
Liver
0%
Lung
0%
Bone Marrow
0%
Heart
0%
Gene Interaction Network
Click a node to explore
NEFLDESKIF5AKIF5BKIF5CKLC1SYT1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt P07196
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.99LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.75 [0.57–0.99]
RankingsWhere NEFL stands among ~20K protein-coding genes
  • #1,112of 20,598
    Most Researched309 Β· top 10%
  • #1,304of 5,498
    Most Pathogenic Variants51 Β· top quartile
  • #9,437of 17,882
    Most Constrained (LOEUF)0.99
Genes detectedNEFL
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis.
PMID: 35025605
Science Β· 2022
1.00
2
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank.
PMID: 38735950
BMC Med Β· 2024
0.90
3
Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications.
PMID: 41015047
Lancet Neurol Β· 2025
0.80
4
Plasma proteomics identifies proteins and pathways associated with incident epilepsy.
PMID: 41253148
Cell Rep Med Β· 2025
0.70
5
Decreasing ganglioside synthesis delays motor and cognitive symptom onset in Spg11 knockout mice.
PMID: 38876323
Neurobiol Dis Β· 2024
0.68